~~<i id='8A4A6987EF'><strike id='8A4A6987EF'><tt id='8A4A6987EF'><pre id='8A4A6987EF'></pre></tt></strike></i>~~

Home» comprehensive» comprehensive

comprehensive

author：hotspot 2025-10-04 06:04:22 Page View：34

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Pfizer's RSV vaccine recommended for approval in Europe
Next article： What does generative AI mean for health care? We asked experts

explore

Trump demands the U.S. pay no more for drugs than other countries … again

EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

The Karikó problem: Lessons for funding basic research

AdobeNewscientificinstitutesarespringingupallovertheplacethesedays:ArcadiaScience,NewScience,ArcInst

Sports medicine is finally prioritizing gender equality

MollyFergusonforSTATWhencyclistAlisonTetrickjoinedthesport’sprofessionalranks,shereceivedtheperkstha

Washington Commanders' Dan Snyder ordered to pay NFL $60M following investigation

1:30WashingtonCommandersownersDanSnyderonthefieldbeforetheDallasCowboysdefeatoftheWashingtonCommande